Iovance Biotherapeutics Announces Q3 2024 Earnings Call
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is gearing up to share its third quarter and year-to-date financial results. This well-reputed biotechnology company specializes in pioneering polyclonal tumor infiltrating lymphocyte (TIL) therapies aimed at improving outcomes for cancer patients. Set to take place on the evening of November 7, 2024, at 4:30 p.m. EST, this conference call will provide vital insights into the company's financial health and operational updates.
Details of the Earnings Call
The management team will host a live audio webcast, providing an opportunity for investors and interested parties to engage with the results and receive a comprehensive corporate update. Should you miss the live event, there will be archived access for one year following the presentation. Interested participants can register for the call through the company's investor relations website.
Significant Upcoming Conferences
Alongside the financial call, Iovance will also participate in the prestigious Society for Immunotherapy of Cancer (SITC) 2024 event happening from November 6-10, 2024. These gatherings promise not only exciting discussions but also the unveiling of critical research findings. Notably, on November 8, Iovance is scheduled to present groundbreaking results from its studies on lifileucel, further emphasizing the company's commitment to investigative research in cancer treatment.
Key Presentations at SITC 2024
Distingushing features of Iovance's presentations include:
- Abstract #409, showcasing multimodal single-cell sequencing analysis that uncovers potential tumor-reactive populations in lifileucel TIL products.
- A late-breaking report on Abstract #1488 detailing a multicenter Phase 2 trial evaluating lifileucel combined with pembrolizumab for patients with checkpoint inhibitor-naïve metastatic non-small cell lung cancer.
- Abstract #416 presenting superior anti-tumor activity data for the IL12-engineered TIL IOV-5001.
Stifel Healthcare Conference Appearance
Iovance senior leadership will also be featured in a fireside chat at the Stifel 2024 Healthcare Conference on November 19, 2024. This engagement is anticipated to further highlight the company’s strategic vision and innovations within cell therapy.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is fully dedicated to revolutionizing cancer treatment through its advanced TIL therapies. With a strong focus on harnessing the power of the immune system, the company aims to provide effective solutions for challenging cancer types. Their Amtagvi™ is not only pioneering in the field but has also received FDA approval for a solid tumor indication, marking a critical milestone in innovative cancer therapies.
Company’s Commitment to Innovation
Iovance continues to explore the frontiers of TIL therapy and cell engineering, aiming to enhance and prolong life for cancer patients. Beyond just treatment, their research includes gene-edited cell therapy advancements, putting them at the forefront of medical science.
Contact Information
For more inquiries regarding financial results or corporate communications, you may reach the dedicated team at Iovance:
Iovance Biotherapeutics, Inc.:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com
Jen Saunders
Senior Director, Investor Relations & Corporate Communications
267-485-3119
Jen.Saunders@iovance.com
Frequently Asked Questions
What is the date of Iovance’s Q3 2024 earnings call?
The earnings call is scheduled for November 7, 2024, at 4:30 p.m. EST.
How can I access the earnings call?
The earnings call will be live-streamed and archived for one year. Details for registration will be available on Iovance’s investor relations website.
What key conferences is Iovance participating in?
Iovance is participating in the SITC 2024 from November 6-10 and will present findings from recent studies.
What is Amtagvi™?
Amtagvi™ is the first FDA-approved T cell therapy for a solid tumor indication developed by Iovance.
Who should I contact for more information about Iovance?
For inquiries, you may contact Sara Pellegrino or Jen Saunders using the provided email addresses.
